New study sheds light on the dangers of work-related stress

Anyone needing further reason to take that extra day off this summer is in luck. A new study from the National Bureau for Economic Research in the United States gives conclusive proof that work-related stress produces negative health consequences.

In a paper titled “No pain, no gain: the effects of exports on effort, injury and illness” researchers matched health records for Danish workers in the manufacturing sector to production at various companies and found that the better the company’s performance measured by increases in exports the more employees suffered from health problems ranging from depression, cardiovascular disease and on-the-job injuries.

“We find that rising exports lead to higher rates of injury, for both men and women, and sickness, mainly for women,” say the study’s authors.

And while numerous studies over the years have linked job stress with workers’ ill-health, the correlative connection between the two has always left room for doubt about how tight the link might be. Merely to observe that lawyers in high-pressure firms, for example, are more apt to develop high blood pressure does not prove that job stress was the cause of the health concern, since it’s possible that high stress jobs attract people already pre-disposed to have issues with high blood pressure.

The present study avoids this type of uncertainty by tracking rises in negative health outcomes directly with increases in a company’s productivity. “The medical literature typically finds that people who work longer hours have worse health outcomes -but we try to distinguish between causality and correlation,” said Chong Xiang, an economics professor at Purdue and coauthor on the paper.

The study’s authors found that 10 per cent increases in a company’s exports push up female employees’ chance of severe job injury by 6.35 per cent, severe depression by 2.51 per cent, the use of medication for heart attack and stroke by 7.70 per cent and hospitalizations due to heart attack or stroke by a whopping 15.01 per cent.

When comparing firms that performed well with those that performed in the top 25 per cent of export companies, researchers arrived at some interesting results. While the majority of high-performing companies saw employees taking fewer sick days than normal -presumably because work loads pushed them to stay at work -employees in the very top performing companies actually took more sick days than normal, likely because they became overworked to the point where they were forced to take time off.

“Our findings capture the pain from globalization, and we quantify its magnitude relative to the gains from globalization documented by previous research,” say the study’s authors.

A 2010 study found that more than one in four Canadians described their daily lives as highly stressful, with six in ten of highly stressed individuals stating that work was the primary source of their stress. White collar Canadians more often reported their jobs to be highly stressful than their blue-collar peers and men aged 35 to 49 proved to be the cohort with the highest self-reported work-related stress. The economic costs of work-related illness are high -mental health problems alone are said to cost employers an estimated $20 billion annually.

More Cantech Science

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you sell your Rezolve AI stock?

In a March 31 report, Roth Capital Markets analyst Rohit Kulkarni maintained his “Buy” rating on Rezolve AI (Rezolve AI… [Read More]

13 hours ago

This Canadian aerospace stock is a buy, TD says

In a March 31 note, TD Cowen analyst Tim James maintained his “Buy” rating on Magellan Aerospace (Magellan Aerospace Stock… [Read More]

13 hours ago

This investor likes IBM right now

In an appearance on BNN Bloomberg Market Call on March 27, Velocity Investment Partners chief investment officer Brianne Gardner said… [Read More]

21 hours ago

Is Intermap Technologies a buy right now?

Beacon Securities analyst Russell Stanley maintained his “Buy” rating and C$3.00 target on Intermap Technologies  (Intermap Technologies Stock Quote, Chart,… [Read More]

22 hours ago

BRP wins price target raise at Desjardins

Desjardins analyst Benoit Poirier reiterated his “Buy” rating on BRP (BRP Stock Quote, Chart, News, Analysts, Financials TSX:DOO) and raised… [Read More]

2 days ago

Is Auxly Cannabis a buy right now?

In a March 27 report, Haywood analyst Neal Gilmer reiterated his “Buy” rating and $0.25 target price on Auxly Cannabis… [Read More]

2 days ago